Duchenne muscular dystrophy
Not yet recruitingStudy on the Safety and Effectiveness of DT-DEC01 for Patients with Duchenne Muscular Dystrophy
Study on the Safety and Effectiveness of DT-DEC01 for Patients with Duchenne Muscular Dystrophy
- Disease:Duchenne muscular dystrophy
- Substances:Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from duchenne muscular dystrophy affected DONOR
Poland- Participants:0–17 years
- Substances:Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from duchenne muscular dystrophy affected DONOR
- Sponsor:Dystrogen Therapeutics Technology Polska Sp. z o.o.
